Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
Andrew M. South(Kidney Research UK), Matthew A. Sparks(Duke University), Daniel Edmonston(Duke University), Swapnil Hiremath(Apple (Israel)), Laurie A. Tomlinson(London School of Hygiene & Tropical Medicine)
Cited by 292
Related Papers
Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension
|Journal of Hypertension|2023|245
FGF23 at the crossroads of phosphate, iron economy and erythropoiesis
|Nature Reviews Nephrology|2019|239
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States
|American Journal of Kidney Diseases|2020|234
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
|The Lancet Respiratory Medicine|2021|224
FGF23 and klotho at the intersection of kidney and cardiovascular disease
|Nature Reviews Cardiology|2023|116